Straits Times Index
3,336.59 +13.21 (+0.40%) Nikkei
38,952.01 +464.11 (+1.21%) Hang Seng
18,079.61 -150.59 (-0.83%) FTSE 100
8,275.38 +44.33 (+0.54%) Bitcoin USD
67,863.05 +44.59 (+0.07%) CMC Crypto 200
1,463.62 +35.05 (+2.45%)
SPRB Jun 2024 1.000 put
| Previous close | 0.3300 |
| Open | N/A |
| Bid | 0.0000 |
| Ask | 0.9500 |
| Strike | 1.00 |
| Expiry date | 2024-06-21 |
| Day's range | 0.3300 - 0.3300 |
| Contract range | N/A |
| Volume | |
| Open interest | 5 |
Business WireSpruce Biosciences to Participate in the Jefferies Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 23, 2024--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the Jefferies Global Healthcare Conference on June 5, 2024, at 5:00 p.m. ET.
Business WireSpruce Biosciences Announces Poster Presentations at the 2024 Annual Meeting of the Endocrine Society
SOUTH SAN FRANCISCO, Calif., May 22, 2024--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that three submitted abstracts were accepted for the 106th Annual Meeting of the Endocrine Society (ENDO 2024) taking place June 1-4, 2024, in Boston.
ZacksSpruce Biosciences, Inc. (SPRB) Reports Q1 Loss, Tops Revenue Estimates
Spruce Biosciences (SPRB) delivered earnings and revenue surprises of 12.50% and 79.55%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
